Invenomic Capital Management LP Buys 1,375,647 Shares of Acadia Healthcare Company, Inc. $ACHC

Invenomic Capital Management LP lifted its stake in Acadia Healthcare Company, Inc. (NASDAQ:ACHC) by 71.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,312,043 shares of the company’s stock after buying an additional 1,375,647 shares during the period. Acadia Healthcare comprises approximately 2.2% of Invenomic Capital Management LP’s holdings, making the stock its 6th largest holding. Invenomic Capital Management LP owned approximately 3.59% of Acadia Healthcare worth $46,998,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Acadia Healthcare in the first quarter valued at $1,600,000. Goldman Sachs Group Inc. lifted its holdings in shares of Acadia Healthcare by 21.1% during the first quarter. Goldman Sachs Group Inc. now owns 698,225 shares of the company’s stock valued at $21,170,000 after acquiring an additional 121,444 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Acadia Healthcare by 8.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 340,916 shares of the company’s stock worth $10,337,000 after purchasing an additional 27,207 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of Acadia Healthcare by 531.5% in the 2nd quarter. American Century Companies Inc. now owns 105,739 shares of the company’s stock worth $2,399,000 after purchasing an additional 88,995 shares during the last quarter. Finally, Prudential Financial Inc. increased its position in shares of Acadia Healthcare by 21.9% during the 2nd quarter. Prudential Financial Inc. now owns 9,903 shares of the company’s stock worth $225,000 after purchasing an additional 1,780 shares in the last quarter.

Wall Street Analysts Forecast Growth

ACHC has been the topic of several research analyst reports. TD Cowen upped their price objective on shares of Acadia Healthcare from $24.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th. Royal Bank Of Canada lifted their target price on shares of Acadia Healthcare from $28.00 to $31.00 and gave the company an “outperform” rating in a research note on Monday, May 4th. KeyCorp restated an “overweight” rating and set a $30.00 price target on shares of Acadia Healthcare in a research report on Wednesday, May 27th. Guggenheim raised their price target on Acadia Healthcare from $26.00 to $31.00 and gave the company a “buy” rating in a report on Monday, May 4th. Finally, UBS Group boosted their price objective on Acadia Healthcare from $27.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, April 17th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $26.85.

Acadia Healthcare Trading Down 6.0%

Shares of NASDAQ ACHC opened at $23.50 on Thursday. Acadia Healthcare Company, Inc. has a 1-year low of $11.43 and a 1-year high of $30.20. The company has a 50-day moving average of $25.53 and a two-hundred day moving average of $20.23. The company has a market cap of $2.16 billion, a PE ratio of -1.92, a P/E/G ratio of 8.34 and a beta of 0.69. The company has a current ratio of 1.71, a quick ratio of 1.71 and a debt-to-equity ratio of 1.27.

Acadia Healthcare (NASDAQ:ACHC) last released its quarterly earnings results on Wednesday, April 29th. The company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.28 by $0.09. Acadia Healthcare had a negative net margin of 32.84% and a positive return on equity of 7.09%. The business had revenue of $828.80 million for the quarter, compared to analysts’ expectations of $823.51 million. During the same period in the prior year, the firm earned $0.40 earnings per share. Acadia Healthcare’s revenue was up 7.6% compared to the same quarter last year. Acadia Healthcare has set its Q2 2026 guidance at 0.300-0.400 EPS. As a group, equities analysts expect that Acadia Healthcare Company, Inc. will post 1.5 earnings per share for the current fiscal year.

Acadia Healthcare Profile

Acadia Healthcare Company, Inc (NASDAQ: ACHC) is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.

Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.